Abstract:Abstract Background Mesalazine (5-ASA) is a key initial treatment of ulcerative colitis (UC); recent studies have highlighted the role of the gut microbiota in 5-ASA metabolism. There is no established means of predicting treatment outcome. We sought to investigate changes in the gut microbiota and metabolome with 5-ASA treatment, and whether such changes may reflect clinical outcomes. Methods Longitudinal faeces, serum and urine samples were collected from patients with newly diagnosed UC before and after 5-ASA treatment. We documented longitudinal microbiota and metabolome changes with 5-ASA treatment and compared baseline gut microbiota and metabolome in responders (simple clinical colitis activity index (SCCAI) of <4 and faecal calprotectin (FC) of <100 μg/g) and non-responders to 5-ASA. Stool bacterial profiling was performed via 16S rRNA gene sequencing of the V1/V2 hypervariable regions. Host and microbial metabolites in stool, serum and urine were detected and semi-quantitated using liquid chromatography mass spectroscopy (LC-MS) and nuclear magnetic resonance spectroscopy (1H-NMR). Kruskal-Wallis tests and paired analyses using a Wilcoxon rank test were used and p values were adjusted using Benjamini-Hochberg false discovery rate (FDR) correction. Results 37 patients newly diagnosed with UC were recruited. Samples were collected at baseline and a median of 83 days (IQR 22.5 days) later; there were 27 responders and 10 non-responders. Comparing pre- and post- 5-ASA treatment samples demonstrated a reduction in gut microbial α diversity (P=0.01) (Fig 1). Faecal methionine increased with 5-ASA (P=0.04) in all patients, and isovalerate reduced with 5-ASA (P<0.01). Similar reductions after 5-ASA were noted in serum glycoprotein B (GlycB) (P=0.02). At baseline, responders tended to have increased α diversity compared to non-responders, but not statistically significantly (P=0.09). Similarly, there were β diversity differences, although these did not reach significance (P=0.06). At baseline non-responders had a higher relative stool abundance of Bacteroidetes and Firmicutes (P<0.01) compared to responders. Agathobacter, Coprococcus and Blautia genera were enriched in non-responders (P=0.05). At baseline, urinary hippurate was higher in patients going on to respond to 5-ASA compared to non-responders (P=0.04); faecal lysine (P<0.01) and putrescine (P=0.01) levels were also higher in non-responders at baseline. 5-ASA responders had reductions in faecal 2-methylbutyrate and isobutyrate (P=0.02) longitudinally. Conclusion We have shown that baseline relative abundance of certain taxa (such as Blautia), urinary Hippurate and faecal lysine reflect response to 5-ASA. Alterations in the gut microbiome and metabolome are associated with 5-ASA treatment.

Combination of Corticosteroids and 5-Aminosalicylates or Corticosteroids Alone for Patients with Moderate-Severe Active Ulcerative Colitis: A Global Survey of Physicians' Practice

P312 Combination Corticosteroids With, 5-Aminosalicylic Acid Versus Corticosteroids Alone in the Treatment of Hospitalized Patients with Acute Severe Ulcerative Colitis: A Multi-Center Randomized Controlled Trial

Corticosteroids and Mesalamine Versus Corticosteroids for Acute Severe Ulcerative Colitis: A Randomized Controlled Trial

CORTICOSTEROIDS AND 5ASA VERSUS CORTICOSTEROIDS ALONE FOR ACUTE SEVERE ULCERATIVE COLITIS: A RANDOMIZED CONTROLLED TRIAL

Efficacy Of Single Vs Multiple Doses Of 5-Aminosalicylic Acid (5-Asa) In The Treatment Of Mild-Moderate Ulcerative Colitis: An Open Randomized Clinical Trial

Clinical study of mesalazine alone and in combination with steroids in treatment of ulcerative colitis

P880 The real-world use of five-aminosalicylate (5ASA) treatment for Ulcerative Colitis in Australia and New Zealand: Crohn’s Colitis Cure (CCC) data insight’s program

Corticosteroid Therapy in Ulcerative Colitis: Clinical Response and Predictors.

Comparison of the Efficiency of Different Enemas on Patients with Distal Ulcerative Colitis

Corticosteroids Combined with Infliximab Vs. Corticosteroids Sequential Infliximab for Acute Severe Ulcerative Colitis with Mucosal Deficiency: a Retrospective Study

P296 Stopping 5-Aminosalicylic Acid in Patients with Ulcerative Colitis Who Are in Clinical Remission Does Not Increase Risks of Flare

Stopping 5‐Aminosalicylic Acid in Ulcerative Colitis Patients in Corticosteroid‐free remission is not associated with Increased Risk of Flare: A Territory‐wide population‐based cohort study

5-aminosalicylic acid as a maintenance therapy for ulcerative colitis:an analysis of 114 cases

P561 Reasons for low use of topical 5-ASA formulations in patients treated for ulcerative colitis: comparison of doctors and patients perspectives

No increased risk of flare in ulcerative colitis patients in corticosteroid-free remission after stopping 5-aminosalicylic acid: A territory-wide population-based study

P1000 A meta-analysis and systematic review of 5-aminosalicylates withdrawal in Inflammatory Bowel Disease

P1209 Baseline gut microbiota composition and function reflect response to 5-ASA treatment in Ulcerative Colitis

P667 Benefit of 5-ASA continuation on UC disease outcomes following initiation of a biologic

5-Aminosalicylic Acid Prevents Disease Behavior Progression and Intestinal Resection in Colonic and Ileocolonic Crohn's Disease Patients: A Retrospective Study.

P1004 Proportion of agents for refractory ulcerative colitis and the efficacy of immunomodulator in 5-aminosalicylic acid intolerance

Enhancing Oral 5-ASA Effectiveness in Mild-to-Moderate Ulcerative Colitis through an H. erinaceus-Based Nutraceutical Add-on Multi-Compound: The "HERICIUM-UC" Two-Arm Multicentre Retrospective Study